This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: November 15, 2012
Last updated: April 2, 2014
Last verified: April 2014
To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran exposure (in Part II)

Condition Intervention Phase
Healthy Drug: dabigatran etexilate Drug: ticagrelor Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) [ Time Frame: 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours ]
    Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval τ (AUCτ,ss).

  • Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss) [ Time Frame: 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours ]
    Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss).

Enrollment: 48
Study Start Date: November 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Reference (Part 1/A, Part 2/C)
multiple doses of dabigatran (alone)
Drug: dabigatran etexilate
medium dose dabigatran
Experimental: Test 1 (Part 1/Treatment B)
concomitant administration of dabigatran and ticagrelor
Drug: dabigatran etexilate
multiple doses of dabigatran
Drug: ticagrelor
loading dose of ticagrelor
Drug: ticagrelor
multiple doses of ticagrelor
Experimental: Test 2 (Part 2/Treatment D)
staggered administration of ticagrelor and dabigatran
Drug: ticagrelor
loading dose of ticagrelor
Drug: dabigatran etexilate
single dose of dabigatran


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

1. Healthy male subjects.

Exclusion criteria:

1. Any relevant deviation from healthy conditions.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01734772

1160.142.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT01734772     History of Changes
Other Study ID Numbers: 1160.142
2012-002656-16 ( EudraCT Number: EudraCT )
Study First Received: November 15, 2012
Results First Received: April 2, 2014
Last Updated: April 2, 2014

Additional relevant MeSH terms:
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Anticoagulants processed this record on September 21, 2017